Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
Study sponsor: Agios Pharmaceuticals, Inc. · AGIO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-03Actual
Enrollment · participants90Actual
Source updated2025-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.